Global Market Comments
July 14, 2020
Fiat Lux
Featured Trade:
(UPDATE ON THE COVID-19 VACCINE FRONTRUNNER)
(AZN), (MRNA), (RHHBY), (LLY), (PFE), (JNJ)
With the flu season just around the corner and herd immunity nowhere in sight, the pressure to develop a COVID-19 vaccine becomes even more urgent. From where things stand right now though, it looks like we could have a vaccine either already available on the market or ready to hit the market around this time in 2021.
We know we’ll need hundreds of millions of vaccine doses, and the majority of the vaccine programs today are getting built on industrial-scale vaccine platforms. This is positive news.
On an even more positive update, a handful of biotechnology and health care companies are now on late-stage testing for the COVID-19 vaccine.
Leading the charge so far is AstraZeneca (AZN), which received $1.2 billion in financial assistance courtesy of the US government’s Operation Warp Speed program.
AstraZeneca is working on an experimental vaccine, called AZD1222, with the University of Oxford and China National Pharmaceutical Group (Sinopharm).
So far, this is the only COVID-19 vaccine candidate in late-stage Phase 3 trials.
The trials are scheduled to be conducted in different countries, with some already in progress in South Africa, Brazil, and of course, the UK.
The stage will enroll over 10,000 people in the UK alone. The goal is to determine AZD1222’s efficacy in a sizeable group aged 18 and older.
What we know about AstraZeneca’s vaccine candidate is that it’s created from a weakened version of adenovirus, which comes from one of the virus types that causes the common cold. It also includes genetic material from COVID-19, which was added to help the patient’s body recognize the pathogen and trigger a defense mechanism to fight off the infection.
Researchers say that the best-case scenario is for the Phase 3 efficacy results of the AstraZeneca vaccine to be available by this fall.
However, AstraZeneca remains an attractive stock even sans its Covid-19 program thanks to its remarkable drug pipeline. With the foresight to stockpile drugs during this pandemic, the company’s earnings are projected to continuously grow.
In the past five to six years, AstraZeneca has been aggressive in investing in its pipeline to combat patent losses. Now, the company joins Roche (RHHBY) and Eli Lilly (LLY) in the list of companies with the most innovative candidates that are poised to launch commercial products capable of driving growth in the next decade.
A notable growth driver for AstraZeneca is its cancer franchise, particularly its key drug Tagrisso, which is set to tap into a massive market.
Before AstraZeneca was dubbed the leader in the COVID-19 vaccine race, there was Moderna (MRNA). Actually, this small biotechnology company is also expected to begin its late-stage Phase 3 trial in July.
Like AstraZeneca, Moderna is also one of the companies included in the Operation Warp Speed project and received $483 million from the government.
Unlike AstraZeneca, Moderna appears to be experiencing delays due to conflicts between the company’s experts and the US government scientists.
While Moderna shares jumped by over 200% since the pandemic started, these reported tensions represent a risk for its investors. It is particularly alarming because the company is a clinical-stage biotechnology company with no marketed products.
Although Moderna’s timeline remains to be the most aggressive, it could easily drown in the competition.
Keep in mind that other companies competing for the top spot in the COVID-19 race are all established and armed with extensive experience in launching new drugs to market. The list includes Pfizer (PFE), which has a market capitalization of $185.86 billion, and Johnson & Johnson (JNJ) with $375.40 billion.
Needless to say, the inexperience of companies like Moderna could prove to be a handicap in this highly competitive race.
Global Market Comments
July 13, 2020
Fiat Lux
Featured Trade:
(MARKET OUTLOOK FOR THE WEEK AHEAD, or HERE COME HERD IMMUNITY),
(INDU), (TSLA), (SPY), (GLD), (JPM), (IBB), (QQQ), (AAPL), (MSFT), (DCUE), (NVDA)
The US passed a single-day record of 70,000 new cases for Covid-19 over the weekend, with Florida bringing in an astounding 15,300.
We missed a chance to stop the epidemic in January because we were blind. Then we missed again in April because we were lazy, when New York City was losing nearly 1,000 souls a day and ignored the lessons therein.
So, we relentlessly continue our march towards herd immunity, when two-third of the population gets the disease, protecting the remaining one third. That’s about a year off.
That implies total American deaths will reach 2.2 million, more than we have lost from all our wars combined.
The faster people die, the closer we are to the end of the plague, which is good news for everyone.
And the stock market keeps going up every day, the worse the news, the faster. That may be happening because the more severe the shock to the system, the faster companies must evolve to survive, making them ever more profitable.
Out with the Old America, in with the new. The future is happening fast.
We here at Mad Hedge Fund Trader have just delivered the most astonishing quarter in our 13-year record, up some 41.98% from the March 16 low.
That makes me cautious. Things never stay that good for long. Just because I can’t see the next black swan doesn’t mean it isn’t going to happen.
If stocks rise when corona cases are exploding, what do they do when cases fall? Do they fall too, or do they rise even faster?
That’s above my pay grade. I’m only a captain, not a general.
So, I will be moving to a 100% cash position in coming days and then let the next black swan tell me what to do. If we suffer a severe dive, and 10%-20% is entirely possible, then I’ll jump back in with my “BUY” hat on. That means testing the lower up of my six-month (SPX) 2,700-$3,200 range.
If we suddenly surge to far greater heights and new all-time highs, then I will be selling short as fast as I can write the trade alerts.
In the meantime, we have Q2 earnings to look forward to in the coming week, which will certainly be one for the history books. The bullish view is that they will be down only 44% from a dismal Q1. The bearish view is far worse. Banks (JPM) kick off on Tuesday.
NASDAQ (QQQ) hit a new high at 10,622, with Apple (AAPL) and Microsoft (MSFT) leading the charge. Elon Musk is now looking at another $1.7 billion payday with his shares touching $1,500. I’m moving to 100% cash, peeling off one profitable position a day as each option play reaches its maximum profit. I just had the best quarter in a decade, up an eye-popping 40%, and I’m just not that smart to keep it going. Humility always wins in the long-term.
Goldman Sachs chopped its growth forecast in the face of soaring Covid-19 cases, paring their Q3 prediction from +33% to +25%. Political campaign rallies are spreading the disease faster than expected. Q1 most likely came in at negative -5%. Expect worse to come. If the stock market can’t break at 135,000 corona deaths, it will at 260,000 or 520,000, which is certainly coming.
NVIDIA topped Intel as most valuable chip company. No surprise here. High-end graphics cards are worth a lot more money than plain commodity processors. Keep buying dips on (NVDA) which we’ve been loading the boat with now for four years. There’s an easy double from here.
Warren Buffet bought Dominion Energy (DCUE), in one of the only distressed sales available this year, thanks so much to government support. With natural gas prices at all-time lows, the big boys are throwing in the towel. Immense public pressure is forcing public utilities to abandon fossil fuels. Warren will sell all of his newfound energy in the $10 billion deal to China. It’s the beginning of the end for carbon. Buy (TSLA) on dips.
Dividend Cuts will drive stock trading in H2. Energy, airline, cruise lines, casinos, movie theaters, and hotels are most at risk, while big technology companies like Apple are the safest. Currently, the S&P 500 is yielding 2.0%, while the ten-year US Treasury bond is paying out 0.65%. Room for a cut?
Tesla to reach $100 billion in annual revenue by 2025, says San Francisco-based JMP Securities. The logic goes that if they can produce 90,000 vehicles a quarter during a pandemic, 140,000 a quarter should be no problem by yearend. The news delivered a move in the shares to a new all-time high of $1,549. Inclusion of (TSLA) in the S&P 500 would also deliver a lot of forced institutional buying, which might take the shares up 40% more. The future is happening fast. Keep buying (TSLA) on dips for a 2021 target of $2,500. If this keeps up, we may see it next week. Remember, I traded Tokyo in 1989. Nothing is impossible.
US student visas were canceled in ostensibly an administration coronavirus-fighting measure, but really in the umpteenth measure to shut foreigners out. “America first” is turning into “America only.” Midwestern schools in particular will be hurt by the loss of 400,000 full tuition-paying international students, especially when state education budgets are getting cut to the bone. That’s down from 800,000 three years ago. If they’re already here, how does this help us? Most colleges are moving to online-only models to limit infections.
When we come out the other side of this, we will be perfectly poised to launch into my new American Golden Age, or the next Roaring Twenties. With interest rates still at zero, oil cheap, there will be no reason not to. The Dow Average will rise by 400% or more in the coming decade.
My Global Trading Dispatch enjoyed another blockbuster week, up an astounding +2.28. It was a week when everything worked in the extreme….again.
My eleven-year performance rocketed to a new all-time high of 381.74%. A triple weighting in biotech and a double weighting in gold were a big help. A foray into the banks proved immediately successful. I seem to have the Midas touch these days.
That takes my 2020 YTD return up to an industry-beating +25.83%. This compares to a loss for the Dow Average of -8.8%, up from -37% on March 23. My trailing one-year return popped back up to a record 66.22%, also THE HIGHEST IN THE 13-YEAR HISTORY of the Mad Hedge Fund Trader. My eleven-year average annualized profit recovered to a record +36.07%, another new high.
The only numbers that count for the market are the number of US Coronavirus cases and deaths, which you can find here. It’s jobs week and we should see an onslaught of truly awful numbers.
On Monday, July 13 at 10:00 AM EST, the June Inflation Expectations are out.
On Tuesday, July 14 at 7:30 AM EST, US Core Inflation for June is published
On Wednesday, July 15, at 7:30 AM EST, US Industrial Production for June is announced. At 10:30 AM EST, the EIA Cushing Crude Oil Stocks are out.
On Thursday, June 16 at 8:30 AM EST, Weekly Jobless Claims are announced. At 7:30 AM, US Retail Sales for June is printed.
On Friday, June 17, at 7:30 AM EST, the US Housing Starts for June are released.
The Baker Hughes Rig Count is out at 2:00 PM EST.
As for me, I am training hard for my upcoming 50-mile hike with the Boy Scouts, knocking off 10 miles a day at 9,000 feet on the Tahoe Rim Trail. I have to confess that I’m feeling the knees like never before.
As they used to say in the Marine Corps, “Pain is fear leaving the body.” More than knowledge comes with age. Pain is there as well.
Marine Corps to Boy Scout leader. It’s been a full life.
Stay healthy.
John Thomas
CEO & Publisher
The Diary of a Mad Hedge Fund Trader
The Years Have Not Been Kind
“Send us your freaks,” said an Amazon human resources executive to a temp agency during its early days.
Global Market Comments
July 10, 2020
Fiat Lux
Featured Trade:
(HOW TO HANDLE THE FRIDAY, JULY 17 OPTIONS EXPIRATION),
(REGN), (ILMN), (SGEN), (JPM)
Followers of the Mad Hedge Fund Trader alert service have the good fortune to own FOUR deep in-the-money options positions that expire on Friday, July 17, and I just want to explain to the newbies how to best maximize their profits.
These involve the:
Seattle Genetics (SGEN) 7/140-$145 call spread
Illumina (ILMN) 7/$320-$330 call spread
Regeneron (REGN) 7/$570-$580 call spread
JP Morgan Chase (JPM) 7/$80-$85 call spread
Provided that we don’t have another 3,000-point move down in the market by next week, these positions should expire at their maximum profit points.
So far, so good.
I’ll do the math for you on our oldest and least liquid position which I almost certainly will run into expiration. Your profit can be calculated as follows:
Profit: $5.00 expiration value - $4.30 cost = $0.70 net profit
(23 contracts X 100 contracts per option X $0.70 profit per option)
= $1,610 or 16.27% in 18 trading days.
Many of you have already emailed me asking what to do with these winning positions.
The answer is very simple. You take your left hand, grab your right wrist, pull it behind your neck, and pat yourself on the back for a job well done.
You don’t have to do anything.
Your broker (are they still called that?) will automatically use your long position to cover your short position, canceling out the total holdings.
The entire profit will be credited to your account on Monday morning July 20 and the margin freed up.
Some firms charge you a modest $10 or $15 fee for performing this service.
If you don’t see the cash show up in your account on Monday, get on the blower immediately and find it.
Although the expiration process is now supposed to be fully automated, occasionally machines do make mistakes. Better to sort out any confusion before losses ensue.
If you want to wimp out and close the position before the expiration, it may be expensive to do so. You can probably unload them pennies below their maximum expiration value.
Keep in mind that the liquidity in the options market understandably disappears, and the spreads substantially widen, when a security has only hours, or minutes until expiration on Friday, July 17. So, if you plan to exit, do so well before the final expiration at the Friday market close.
This is known in the trade as the “expiration risk.”
One way or the other, I’m sure you’ll do OK, as long as I am looking over your shoulder, as I will be, always. Think of me as your trading guardian angel.
I am going to hang back and wait for good entry points before jumping back in. It’s all about keeping that “Buy low, sell high” thing going.
I’m looking to cherry-pick my new positions going into the next month-end.
Take your winnings and go out and buy yourself a well-earned dinner. Just make sure it’s take-out. I want you to stick around.
Well done, and on to the next trade.
You Can’t Do Enough Research
“The stock market is not expensive at 2% Fed funds and 2% government bonds,” said my old investor and mentor Leon Cooperman of Omega Advisors.
Global Market Comments
July 9, 2020
Fiat Lux
SPECIAL EARLY RETIREMENT ISSUE
Featured Trade:
(HOW TO JOIN THE EARLY RETIREMENT STAMPEDE)
Global Market Comments
July 8, 2020
Fiat Lux
Featured Trade:
(TRADING THE BLUE WAVE STOCK MARKET),
(FB), (AAPL), (MSFT), (AMZN), (ADBE), (SQ), (PYPL), (CRM), (SGEN), (REGN), (ILMN) (FEYE), (PANW), (AMD), (MU), (NVDA), (TSLA), (LEN), (PHM), (KBH), (XOM), (CVX), (XOM), (RTN), (NOC), (LMT), (KOL), (X), (GE)
